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Purpose/Objective: Radiotherapy (RT) of lung cancer 
patients could be improved if patient specific dose tolerances 
can be estimated during the first weeks of a fractionated 
treatment course. Such tolerances may be estimated from 
the delivered dose distribution and changes in ventilation and 
respiration patterns extracted from frequently recorded 4D-
Cone Beam CT. 
Materials and Methods: This is a study of 140 non-small-cell 
lung cancer (NSCLC) patients, which were treated with 60-66 
Gy in 30-33 fractions. Measures of ventilation were generated 
by the freeware tool elastix (http://elastix.isi.uu.nl/), which 
was used for deformable registrations between inspiration 
phases and expiratory phases as well as calculation of 
Jacobian determinant images of Elekta XVI 4D-CBCT 
reconstructions. Approximately 3000 recorded XVI scans were 
available for this study group. The mean of the Jacobian 
determinant (MJD) within the healthy lung region was used as 
a measure of the overall lung ventilation during the 
treatment course. Amsterdam Shrouds of the 4D-CBCT 
projections were generated by RTK-software, and the 
respiratory period (ReP) was estimated from the extracted 
respiratory signal. For each patient the slope of linear fits of 
MJD and ReP values vs. fraction number for the first 10 
fractions as well as for the full number of fractions were used 
as measures for ventilation and respiration changes during 
RT. Relative changes (after/before-1) in forced expiratory 
volume in 1 second (FEV1) and forced expiratory vital 
capacity (FVC) before and after the treatment course were 
chosen as clinical endpoints (ΔFEV1 REL and ΔFVCREL). 
A multivariable analysis was performed on ΔFEV1 REL and 
ΔFVCREL respectively as dependent variables with the co-
variables MJD-slope, ReP-slope and mean lung dose (MLD). 
Results: The deformable registrations and calculating MJDs as 
well as estimating RePs from Amsterdam Shrouds were 
carried out successfully for all the 140 patients. In the 
multivariable analysis only MLD was significant in relation to 
ΔFEV1 REL and ΔFVCREL  
(ΔFEV1 REL=-0.006MLD+0.078; pMLD=0.009 and ΔFVCREL=-
0.008MLD+0.115; pMLD=0.002, respectively). Plots of ΔFEV1 REL 
and ΔFVCREL as a function of MLD are shown in the figure. 
Both plots show a declining tendency, indicating that higher 
MLD corresponds to larger decrease in clinically measured 
lung function tests. Spearman correlation coefficient 
between ΔFEV1 REL and ΔFVCREL versus mean lung dose were -
0.249 (p=0.003) and -0.252 (p=0.003), respectively. 
 
Conclusions: In this study it was possible to carry out the 
deformable registrations on the 4D-CBCT-scans, but for the 
current 4D-CBCTimage quality, it was not possible to show an 
association between changes in mean Jacobian or respiration 
period during RT with changes in FEV1 and FVC. 
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Purpose/Objective: Genitourinary (GU) toxicity following 
radiotherapy (RT) for prostate cancer involves the interplay 
between various symptoms. Commonly used toxicity scoring 
systems capture a subset of GU symptoms only. The purpose 
of this study was to investigate the wider range of GU 
toxicity as reported by patients (atomized patient-reported 
outcomes), how such symptoms interact, and to what extent 
their occurrence can be explained by the urinary bladder 
dose. 
Materials and Methods: We applied factor analysis (FA) to 
group 35 patient-reported GU symptoms in four prostate 
cancer cohorts (N=1009). The investigated cohorts included 
patients that were previously treated for localized prostate 
cancer with either primary or salvage external beam RT 
(EBRT), or EBRT combined with brachytherapy at two centres 
during 1993-2007 (time to follow-up: 1-14 years; average age 
at RT: 64-70 years). Prescribed dose was 70-78 Gy in 2 Gy 
fractions. Relationships between maximum or mean absorbed 
dose (Dmax or Dmean; population median of Dmean: 49-54 Gy) to 
the urinary bladder and single/joint symptoms in the 
identified symptom groups were investigated for patients 
treated with primary EBRT using logistic regression and 
receiver operating curve analysis, quantifying the area under 
the curve (Az). 
Results: Three distinct symptom groups, labelled 
Incontinence, Obstruction, and Urgency were consistently 
identified across all cohorts. For patients treated with 
primary EBRT, Dmax predicted multiple joint symptoms of 
Urgency (p=0.02; Az=0.73), and one single or two joint 
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symptoms of Incontinence (p≤0.04; Az=0.59, 0.61). Dmean 
predicted one single or two joint symptoms of Urgency 
(p=0.05; Az=0.57, 0.63). 
Conclusions: Based on a large number of atomized GU 
symptoms and a large number of patients treated at two 
centres, our results suggest that bladder maximum dose is 
particularly critical for patient-reported urinary incontinence 
and urgency after primary EBRT for localized prostate 
cancer. These findings together with a more comprehensive 
modelling approach have the potential to further improve our 
understanding of the complex dose-response of the GU tract. 
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Purpose/Objective: The prolongation of the overall 
treatment time (OTT) has influence in the control probability 
for certain type of tumours [1,2]. We develop a program to 
register interruptions that occur during the treatments and a 
protocol to compensate them with the help of a database. In 
this work we show the main results of applying these 
procedures during 42 months. 
Materials and Methods: We use Microsoft Access 2007© 
software to create a database of the treated patient. The 
more important fields are: demographic data, the ICD code 
of the disease, number of fractions and the dose per fraction, 
starting treatment date, the date in which the treatment 
should finish and the real ending date. If an interruption 
occurs, we register: the reason, the starting date and the 
ending date of it. The treatments were classified in three 
growing categories of prioritising according to the need to 
manage interruptions, using the criteria of [3]. In our 
protocol we try to keep the OTT for category one and 
prostate cancer according to [2] with the use of 
compensatory measures, these are mainly: give two sessions 
in the same day or one fraction with an equivalent dose of 
two fractions. The category two is compensated with 
increased total dose. We made a general analysis of the 
results of the interruptions management with the protocol 
described previously. In addition we categorized the 
treatments by their duration (CD): [0-10], [11-15], [16-28] 
and [29-40] treatment days and we obtained the average 
prolongation days (APD). Finally we studied the benefits of 
applying this protocol to different tumor sites: head and neck 
(HN), lung, cervix and breast (local control rate), and 
prostate (biochemical failure) using the data of [1] and [2]. 
Results: We analyzed 1893 treatments, 82.3% suffered an 
interruption with APD = 4.58, (4.37, 4.79) days, CI(95%). 31% 
of the interruptions had some kind of compensatory measure. 
The upper panel of the figure shows the APD for each one of 
the CD categories, the x-axis represents the treatment days 
median value of the category. The graphic shows a linear 
behavior with the total treatment days. This fact, and the 
high percentage of treatments that are interrupted, make 
necessary to take preventive actions for category 1 cases. 
The table show the absolute increase in TCP for each tumor 
site if we only include the compensatory measure to keep the 
OTT, column 1, and the column 2 is the result including all 
compensatory measures. In parentheses is the quantile of 
patients who have a benefit bigger than 4%. The HN and 
prostate treatments have a high APD because their highest 
duration (upper panel of figure), therefore the protocol pays 
special attention to these pathologies and the benefits are 
greater. The contrary occurs to breast cancer. The lower 
panel of the figure shows the histogram of the benefit in 




Conclusions: A compensatory measures program 
implementation improves the output of the treatments, 
especially in the HN. 
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